Russell Investments Group Ltd. Makes New $547,000 Investment in Organogenesis $ORGO

Key Points

• Russell Investments Group Ltd. acquired 123,131 shares of Organogenesis, valued at approximately $547,000, giving them about 0.10% ownership of the company.
• Analysts have raised the price target of Organogenesis shares from $7.00 to $9.00, with a consensus rating of "Moderate Buy" and an average target price of $7.50.
• Insider Lori Freedman bought 142,379 shares at an average price of $2.91, increasing her ownership in Organogenesis by 20.48%.

Russell Investments Group Ltd. bought a new stake in Organogenesis (NASDAQ:ORGO - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 123,131 shares of the company's stock, valued at approximately $547,000. Russell Investments Group Ltd. owned 0.10% of Organogenesis at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Nuveen LLC acquired a new stake in shares of Organogenesis in the 1st quarter valued at about $742,000. Invesco Ltd. grew its stake in shares of Organogenesis by 779.7% in the 1st quarter. Invesco Ltd. now owns 1,069,252 shares of the company's stock valued at $4,619,000 after buying an additional 947,705 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Organogenesis by 45.3% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 667,529 shares of the company's stock valued at $2,884,000 after buying an additional 208,038 shares during the period. Vanguard Group Inc. grew its stake in shares of Organogenesis by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock valued at $19,144,000 after buying an additional 841,618 shares during the period. Finally, Mackenzie Financial Corp grew its stake in shares of Organogenesis by 65.4% in the 1st quarter. Mackenzie Financial Corp now owns 126,303 shares of the company's stock valued at $546,000 after buying an additional 49,950 shares during the period. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Trading Down 0.6%

NASDAQ ORGO traded down $0.03 during trading hours on Friday, hitting $5.00. The company's stock had a trading volume of 402,012 shares, compared to its average volume of 722,645. Organogenesis has a 52 week low of $2.45 and a 52 week high of $6.71. The company has a market capitalization of $634.30 million, a PE ratio of -35.71 and a beta of 1.75. The company's 50-day simple moving average is $4.62 and its two-hundred day simple moving average is $4.22.

Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. The business had revenue of $101.01 million during the quarter, compared to the consensus estimate of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. Research analysts anticipate that Organogenesis will post -0.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ORGO shares. BTIG Research restated a "buy" rating on shares of Organogenesis in a research note on Tuesday, July 15th. Cantor Fitzgerald raised their target price on Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $7.50.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.